A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a dangerous immune reaction that can cause organ failure. With no specific anti-sepsis therapy currently available, the findings mark a major step forward. Researchers now aim to move into Phase III trials.
Quelle: ScienceDaily | Immunsystem
Titelbild/Grafik: ScienceDaily News
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- Your daily coffee may be protecting your brain, 43-year study finds
- DNA origami vaccines could be the next leap beyond mRNA
- Scientists discover the switch that revives exhausted cancer-fighting T cells
- A bold new plan could finally cure type 1 diabetes
- Is bubble tea bad for you? New research raises red flags
- Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia
- Scientists discover the body’s hidden “off switch” for inflammation
- This reengineered HPV vaccine trains T cells to hunt down cancer
- One in three people carry this brain parasite but the body has a kill switch
- Scientists find a missing link between Epstein-Barr virus and multiple sclerosis
